MEDEZE Reports Q2/2026 Net Profit of THB 40.18 Million, Up 17% QoQ, Advancing Standards and Stem Cell Innovation
Ms. Anchisa Lekphet (right), Chief Accounting and Finance Officer, and Dr. Wasawat Sroithong (left), Investor Relations Officer of Medeze Group Public Company Limited (MEDEZE), jointly presented the Company’s business overview and operating results for the second quarter of 2026 at the listed companies’ Earnings Call (Opp Day), organised by the Stock Exchange of Thailand (SET).
For the second quarter of 2026, the Company reported a net profit of THB 40.18 million, an increase of THB 5.81 million, or approximately 17%, from THB 34.37 million in the previous quarter. Total revenue amounted to THB 170.31 million. The Company’s net profit has shown clear signs of recovery over the past four quarters, rising from THB 30.54 million in Q3/2025, THB 36.43 million in Q4/2025, and THB 34.37 million in Q1/2026 to THB 40.18 million in the current quarter.
MEDEZE continues to build on its business achievements. Most recently, the Company became the first and only organisation in Thailand to meet the Cell Bank Standard. It has also obtained key certifications and credentials, including a modern drug manufacturing licence (Ph.Yor. 2), AABB accreditation, and ISO certification. Furthermore, the Company participates in the Advanced Therapy Medicinal Products (ATMPs) Regulatory Sandbox to help advance Thailand’s stem cell innovation and the development of advanced medicinal products.
Following its achievement of the Cell Bank Standard, the Company continues to strengthen its medical infrastructure. MEDEZE aims to obtain Good Manufacturing Practice (GMP) certification by the fourth quarter of 2026 and commence clinical trials involving stem cell-based treatments for knee osteoarthritis and skin rejuvenation in 2027. The Company also plans to begin the commercial production of cell culture media in 2028 to reduce Thailand’s reliance on imports. In parallel, MEDEZE is expanding into the Philippine market, reinforcing its position as a leader in medical innovation in Thailand and internationally.
For more information, please visit: www.medezegroup.com/th
IR Press Releases